← Back to Search

Insulin Delivery System

Insulin-alone closed-loop for Type 1 Diabetes

N/A
Waitlist Available
Led By Laurent Legault, MD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40-hour intervention
Awards & highlights

Study Summary

This study is evaluating whether a new insulin dosing algorithm is safe for children with type 1 diabetes.

Eligible Conditions
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40-hour intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 40-hour intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time in range
Secondary outcome measures
Coefficient of variance of glucose levels and insulin delivery
Mean glucose levels
Specific nighttime time in range
+3 more

Side effects data

From 2016 Phase 4 trial • 85 Patients • NCT01970241
21%
Hypoglycemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
NPH With Corticosteroid
Control

Trial Design

1Treatment groups
Experimental Treatment
Group I: Insulin alone closed-loopExperimental Treatment1 Intervention
Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor
394 Previous Clinical Trials
998,367 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,618 Previous Clinical Trials
3,201,550 Total Patients Enrolled
Laurent Legault, MDPrincipal InvestigatorMontreal Children's Hospital of the MUHC
3 Previous Clinical Trials
70 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Apr 2025